New drug combo tested for advanced cancers in asian patients
NCT ID NCT03433898
First seen Jan 04, 2026
Summary
This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers like stomach, liver, and lung cancer. The study is now complete, but results are not yet public.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Chang Gung Memorial Hospital(Linkou)
Taoyuan, 333, Taiwan
-
Japanese Foundation for Cancer Research
Tokyo, Koto-ku, 135-8550, Japan
-
Kanagawa Cancer Center
Kanagawa, Yokohama, 241-8515, Japan
-
NCKUH
Tainan, 70403, Taiwan
-
National Cancer Center Hospital
Tokyo, Chuo-ku, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, Kashiwa, 277-8577, Japan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Saitama Cancer Center
Saitama, Kitaadachi-gun, 362-0806, Japan
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital
Seoul, 03722, South Korea
-
Shizuoka Cancer Center
Shizuoka, Sunto-gun, 411-8777, Japan
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ezabenlimab (also called BI 754091) and BI 754111
What this could lead to
If this works, it could point toward a new treatment option for certain advanced cancers like stomach, liver, or lung cancer.
What could go wrong
This is a very early (Phase I) study focused on safety and dosing, not on proving the drugs work. Many early-stage cancer drugs fail to show enough benefit in later trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.